Literature DB >> 17763352

New algorithm for quantifying vascular changes in dynamic contrast-enhanced MRI independent of absolute T1 values.

E Mark Haacke1, Cristina L Filleti, Ramtilak Gattu, Carlo Ciulla, Areen Al-Bashir, Krithivasan Suryanarayanan, Meng Li, Zahid Latif, Zach DelProposto, Vivek Sehgal, Tao Li, Vidya Torquato, Rajesh Kanaparti, Jing Jiang, Jaladhar Neelavalli.   

Abstract

In this work, we present a new method for predicting changes in tumor vascularity using only one flip angle in dynamic contrast-enhanced (DCE) imaging. The usual DCE approach finds the tissue initial T1 value T1(0) prior to injection of a contrast agent. We propose finding changes in the tissue contrast agent uptake characteristics pre- and postdrug treatment by fixing T1(0). Using both simulations and imaging pre- and postadministration of caffeine, we find that the relative change (NR50) in the median of the cumulative distribution (R50) is almost independent of T1(0). Fixing T1(0) leads to a concentration curve c(t) more robust to the presence of noise than calculating T1(0). Consequently, the NR50 for the tumor remains roughly the same as the ideal NR50 when T1(0) is exactly known. Further, variations in eating habits are shown to create significant changes in the R50 response for both liver and muscle. In conclusion, analyzing data with fixed T1(0) leads to a more stable measure of changes in NR50 and does not require knowledge of T1(0). Both caffeine and eating introduce major changes in blood flow that can significantly modify the NR50 and lead to incorrect conclusions regarding drug treatment. Copyright (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17763352     DOI: 10.1002/mrm.21358

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  32 in total

1.  Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging.

Authors:  Rihyeon Kim; Seung Hong Choi; Tae Jin Yun; Soon-Tae Lee; Chul-Kee Park; Tae Min Kim; Ji-Hoon Kim; Sun-Won Park; Chul-Ho Sohn; Sung-Hye Park; Il Han Kim
Journal:  Eur Radiol       Date:  2016-06-29       Impact factor: 5.315

2.  A clinically feasible method to estimate pharmacokinetic parameters in breast cancer.

Authors:  Jun Li; Yanming Yu; Yibao Zhang; Shanglian Bao; Chunxue Wu; Xiaoying Wang; Jie Li; Xiaopeng Zhang; Jiani Hu
Journal:  Med Phys       Date:  2009-08       Impact factor: 4.071

3.  Comparison of Dynamic Contrast-Enhancement Parameters between Gadobutrol and Gadoterate Meglumine in Posttreatment Glioma: A Prospective Intraindividual Study.

Authors:  J E Park; J Y Kim; H S Kim; W H Shim
Journal:  AJNR Am J Neuroradiol       Date:  2020-10-15       Impact factor: 3.825

4.  Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study.

Authors:  Roh-Eul Yoo; Seung Hong Choi; Tae Min Kim; Chul-Kee Park; Sung-Hye Park; Jae-Kyung Won; Il Han Kim; Soon Tae Lee; Hye Jeong Choi; Sung-Hye You; Koung Mi Kang; Tae Jin Yun; Ji-Hoon Kim; Chul-Ho Sohn
Journal:  Eur Radiol       Date:  2016-12-14       Impact factor: 5.315

5.  Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus.

Authors:  Ji Young Yoo; Amy Haseley; Anna Bratasz; E Antonio Chiocca; Jianying Zhang; Kimerly Powell; Balveen Kaur
Journal:  Mol Ther       Date:  2011-10-25       Impact factor: 11.454

6.  The impact of reliable prebolus T 1 measurements or a fixed T 1 value in the assessment of glioma patients with dynamic contrast enhancing MRI.

Authors:  Anna Tietze; Kim Mouridsen; Irene Klærke Mikkelsen
Journal:  Neuroradiology       Date:  2015-03-06       Impact factor: 2.804

7.  Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion.

Authors:  Cornelia Brendle; Johann-Martin Hempel; Jens Schittenhelm; Marco Skardelly; Ghazaleh Tabatabai; Benjamin Bender; Ulrike Ernemann; Uwe Klose
Journal:  Clin Neuroradiol       Date:  2017-05-09       Impact factor: 3.649

8.  Dynamic contrast-enhanced magnetic resonance imaging as a prognostic factor in predicting event-free and overall survival in pediatric patients with osteosarcoma.

Authors:  Junyu Guo; Wilburn E Reddick; John O Glass; Qing Ji; Catherine A Billups; Jianrong Wu; Fredric A Hoffer; Sue C Kaste; Jesse J Jenkins; Ximena C Ortega Flores; Juan Quintana; Milena Villarroel; Najat C Daw
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

9.  Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma.

Authors:  Vaios Hatzoglou; Jung Hun Oh; Olivia Buck; Xuling Lin; Michelle Lee; Amita Shukla-Dave; Robert J Young; Kyung K Peck; Behroze Vachha; Andrei I Holodny; Christian Grommes
Journal:  J Neurooncol       Date:  2018-08-02       Impact factor: 4.130

10.  Feasibility of using limited-population-based average R10 for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced magnetic resonance imaging data.

Authors:  Wei Huang; Ya Wang; David M Panicek; Lawrence H Schwartz; Jason A Koutcher
Journal:  Magn Reson Imaging       Date:  2009-03-17       Impact factor: 2.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.